[{"id":"9af34180-be45-4c8a-9ff0-5e378df0da5b","acronym":"","url":"https://clinicaltrials.gov/study/NCT00577278","created_at":"2021-01-18T02:06:41.516Z","updated_at":"2024-07-02T16:35:19.092Z","phase":"Phase 2","brief_title":"A Phase II Study of Allo-HCT for B-Cell NHL Using Zevalin, Fludarabine and Melphalan","source_id_and_acronym":"NCT00577278","lead_sponsor":"City of Hope Medical Center","biomarkers":" CD20","pipe":"","alterations":" ","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • sirolimus • melphalan • fludarabine IV • Zevalin (ibritumomab tiuxetan)"],"overall_status":"Completed","enrollment":" Enrollment 41","initiation":"Initiation: 10/03/2007","start_date":" 10/03/2007","primary_txt":" Primary completion: 05/30/2019","primary_completion_date":" 05/30/2019","study_txt":" Completion: 12/14/2023","study_completion_date":" 12/14/2023","last_update_posted":"2024-02-16"},{"id":"66d60b16-3085-4c22-820f-c464f0125eec","acronym":"NCI-V02-1691","url":"https://clinicaltrials.gov/study/NCT00031642","created_at":"2021-01-18T00:00:38.427Z","updated_at":"2024-07-02T16:35:25.184Z","phase":"Phase 1/2","brief_title":"Monoclonal Antibody Therapy in Relapsed Non-Hodgkin's After Chemotherapy and Autologous Stem Cell Transplantation","source_id_and_acronym":"NCT00031642 - NCI-V02-1691","lead_sponsor":"University of Nebraska","biomarkers":" CD20","pipe":"","alterations":" ","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • Zevalin (ibritumomab tiuxetan)"],"overall_status":"Completed","enrollment":" Enrollment 26","initiation":"Initiation: 01/01/2002","start_date":" 01/01/2002","primary_txt":" Primary completion: 11/01/2005","primary_completion_date":" 11/01/2005","study_txt":" Completion: 03/01/2008","study_completion_date":" 03/01/2008","last_update_posted":"2023-12-27"},{"id":"a8c65941-392d-4c78-b64d-bcf83077b940","acronym":"","url":"https://clinicaltrials.gov/study/NCT02320292","created_at":"2021-01-18T11:00:10.127Z","updated_at":"2024-07-02T16:35:29.118Z","phase":"Phase 3","brief_title":"Rituximab With or Without Yttrium Y-90 Ibritumomab Tiuxetan in Treating Patients With Untreated Follicular Lymphoma","source_id_and_acronym":"NCT02320292","lead_sponsor":"Mayo Clinic","biomarkers":" BCL2 • B2M","pipe":" | ","alterations":" BCL2 mutation","tags":["BCL2 • B2M"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • Truxima (rituximab-abbs) • Zevalin (ibritumomab tiuxetan) • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Novex (rituximab biosimilar)"],"overall_status":"Completed","enrollment":" Enrollment 20","initiation":"Initiation: 02/11/2015","start_date":" 02/11/2015","primary_txt":" Primary completion: 02/28/2021","primary_completion_date":" 02/28/2021","study_txt":" Completion: 11/09/2023","study_completion_date":" 11/09/2023","last_update_posted":"2023-11-15"},{"id":"f8abd97f-376f-47a2-ae4b-380dbf3c9def","acronym":"","url":"https://clinicaltrials.gov/study/NCT01811368","created_at":"2021-01-18T08:02:05.716Z","updated_at":"2024-07-02T16:35:59.858Z","phase":"Phase 2","brief_title":"Zevalin Before Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma","source_id_and_acronym":"NCT01811368","lead_sponsor":"Joseph Tuscano","biomarkers":" CD20","pipe":"","alterations":" ","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • Zevalin (ibritumomab tiuxetan)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 03/12/2013","start_date":" 03/12/2013","primary_txt":" Primary completion: 04/01/2023","primary_completion_date":" 04/01/2023","study_txt":" Completion: 12/01/2023","study_completion_date":" 12/01/2023","last_update_posted":"2022-11-30"},{"id":"2b6392dc-b1b2-43fe-8479-293200da254b","acronym":"FOLL12","url":"https://clinicaltrials.gov/study/NCT02063685","created_at":"2021-01-18T09:30:18.986Z","updated_at":"2024-07-02T16:36:08.518Z","phase":"Phase 3","brief_title":"Study to Evaluate the Efficacy of Response-adapted Strategy in Follicular Lymphoma","source_id_and_acronym":"NCT02063685 - FOLL12","lead_sponsor":"Fondazione Italiana Linfomi ONLUS","biomarkers":" CD20","pipe":"","alterations":" ","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • bendamustine • Zevalin (ibritumomab tiuxetan)"],"overall_status":"Completed","enrollment":" Enrollment 807","initiation":"Initiation: 07/01/2012","start_date":" 07/01/2012","primary_txt":" Primary completion: 12/01/2021","primary_completion_date":" 12/01/2021","study_txt":" Completion: 12/01/2021","study_completion_date":" 12/01/2021","last_update_posted":"2022-06-21"},{"id":"1c6b5f95-854d-4762-be43-9df4c5060a57","acronym":"","url":"https://clinicaltrials.gov/study/NCT00290511","created_at":"2021-01-18T00:59:24.844Z","updated_at":"2024-07-02T16:36:11.677Z","phase":"Phase 2","brief_title":"Rituximab, Fludarabine, Mitoxantrone, Dexamethasone (R-FND) Plus Zevalin for High-Risk Follicular Lymphoma","source_id_and_acronym":"NCT00290511","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" BCL2","pipe":" | ","alterations":" LDH elevation","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e LDH elevation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • mitoxantrone • fludarabine IV • Zevalin (ibritumomab tiuxetan)"],"overall_status":"Completed","enrollment":" Enrollment 49","initiation":"Initiation: 06/29/2004","start_date":" 06/29/2004","primary_txt":" Primary completion: 02/12/2021","primary_completion_date":" 02/12/2021","study_txt":" Completion: 02/12/2021","study_completion_date":" 02/12/2021","last_update_posted":"2022-04-22"},{"id":"a784b37c-7475-48e5-a676-6d97945d0b8f","acronym":"","url":"https://clinicaltrials.gov/study/NCT00070018","created_at":"2021-01-18T00:10:32.006Z","updated_at":"2024-07-02T16:36:18.609Z","phase":"Phase 2","brief_title":"S0313 Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, and Radiation Therapy Followed By Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Stage I or Stage II Non-Hodgkin's Lymphoma","source_id_and_acronym":"NCT00070018","lead_sponsor":"Southwest Oncology Group","biomarkers":" CD20","pipe":" | ","alterations":" CD20 expression","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Zevalin (ibritumomab tiuxetan)"],"overall_status":"Completed","enrollment":" Enrollment 46","initiation":"Initiation: 02/01/2004","start_date":" 02/01/2004","primary_txt":" Primary completion: 11/01/2010","primary_completion_date":" 11/01/2010","study_txt":" Completion: 01/08/2015","study_completion_date":" 01/08/2015","last_update_posted":"2022-01-11"},{"id":"cc324279-7d0e-4311-8330-cdee2f88dd11","acronym":"ZEVALIN-DUI","url":"https://clinicaltrials.gov/study/NCT01448928","created_at":"2021-01-18T06:00:43.779Z","updated_at":"2025-02-25T17:19:30.568Z","phase":"","brief_title":"Zevalin Post-marketing Surveillance in Japan","source_id_and_acronym":"NCT01448928 - ZEVALIN-DUI","lead_sponsor":"Spectrum Pharmaceuticals, Inc","biomarkers":" CD20","pipe":"","alterations":" ","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zevalin (ibritumomab tiuxetan)"],"overall_status":"Completed","enrollment":" Enrollment 400","initiation":"Initiation: 09/01/2008","start_date":" 09/01/2008","primary_txt":" Primary completion: 01/31/2018","primary_completion_date":" 01/31/2018","study_txt":" Completion: 01/31/2018","study_completion_date":" 01/31/2018","last_update_posted":"2021-10-01"},{"id":"94663f27-cae3-4835-852a-b330f1e4714e","acronym":"","url":"https://clinicaltrials.gov/study/NCT00562978","created_at":"2021-01-18T02:03:09.991Z","updated_at":"2024-07-02T16:36:28.936Z","phase":"Phase 1/2","brief_title":"Yttrium Y 90 Ibritumomab Tiuxetan, Etoposide, Cyclophosphamide, and an AHSCT in Non-Hodgkin's Lymphoma Patients","source_id_and_acronym":"NCT00562978","lead_sponsor":"City of Hope Medical Center","biomarkers":" CD20","pipe":" | ","alterations":" CD20 positive","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • etoposide IV • Zevalin (ibritumomab tiuxetan) • Neupogen (filgrastim)"],"overall_status":"Completed","enrollment":" Enrollment 54","initiation":"Initiation: 05/16/2000","start_date":" 05/16/2000","primary_txt":" Primary completion: 05/21/2018","primary_completion_date":" 05/21/2018","study_txt":" Completion: 05/21/2018","study_completion_date":" 05/21/2018","last_update_posted":"2021-06-18"},{"id":"fd039752-33d5-4e70-92c9-1162a6cf4db0","acronym":"Fol-BRITe","url":"https://clinicaltrials.gov/study/NCT01234766","created_at":"2021-01-18T04:58:01.847Z","updated_at":"2024-07-02T16:36:30.064Z","phase":"Phase 2","brief_title":"Bendamustine and Rituximab Followed by 90-yttrium (Y) Ibritumomab Tiuxetan for Untreated Follicular Lymphoma","source_id_and_acronym":"NCT01234766 - Fol-BRITe","lead_sponsor":"Dartmouth-Hitchcock Medical Center","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • bendamustine • Zevalin (ibritumomab tiuxetan)"],"overall_status":"Completed","enrollment":" Enrollment 39","initiation":"Initiation: 10/01/2010","start_date":" 10/01/2010","primary_txt":" Primary completion: 01/01/2021","primary_completion_date":" 01/01/2021","study_txt":" Completion: 04/01/2021","study_completion_date":" 04/01/2021","last_update_posted":"2021-05-18"},{"id":"766481ec-fdf8-471f-84d7-c6eb79462b60","acronym":"","url":"https://clinicaltrials.gov/study/NCT00591630","created_at":"2021-01-18T02:11:23.277Z","updated_at":"2024-07-02T16:36:35.173Z","phase":"Phase 2","brief_title":"Zevalin/BEAM/Rituximab vs BEAM/Rituximab With or Without Rituximab in Autologous Stem Cell Transplantation","source_id_and_acronym":"NCT00591630","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" CD20 • CD34","pipe":" | ","alterations":" CD20 positive","tags":["CD20 • CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cytarabine • etoposide IV • carmustine • melphalan • Zevalin (ibritumomab tiuxetan)"],"overall_status":"Completed","enrollment":" Enrollment 30","initiation":"Initiation: 11/14/2007","start_date":" 11/14/2007","primary_txt":" Primary completion: 03/05/2020","primary_completion_date":" 03/05/2020","study_txt":" Completion: 03/05/2020","study_completion_date":" 03/05/2020","last_update_posted":"2021-02-02"},{"id":"98aa5ea7-24cd-4774-add2-2b7d5260957a","acronym":"","url":"https://clinicaltrials.gov/study/NCT00058422","created_at":"2021-01-18T00:07:29.664Z","updated_at":"2024-07-02T16:36:38.797Z","phase":"Phase 2","brief_title":"Rituximab and Combination Chemotherapy Combined With Yttrium Y 90 Ibritumomab Tiuxetan in Treating Older Patients With Previously Untreated B-Cell Lymphoma","source_id_and_acronym":"NCT00058422","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" CD20","pipe":"","alterations":" ","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Zevalin (ibritumomab tiuxetan) • Aranesp (darbepoetin alfa) • Neupogen (filgrastim)"],"overall_status":"Completed","enrollment":" Enrollment 65","initiation":"Initiation: 02/10/2003","start_date":" 02/10/2003","primary_txt":" Primary completion: 11/14/2019","primary_completion_date":" 11/14/2019","study_txt":" Completion: 11/14/2019","study_completion_date":" 11/14/2019","last_update_posted":"2020-11-12"},{"id":"8e5dc9f9-b17d-49dc-8cf1-56fc3e426f09","acronym":"","url":"https://clinicaltrials.gov/study/NCT00491491","created_at":"2021-01-18T01:45:24.218Z","updated_at":"2024-07-02T16:36:41.569Z","phase":"Phase 3","brief_title":"Zevalin-beam for Aggressive Lymphoma","source_id_and_acronym":"NCT00491491","lead_sponsor":"Sheba Medical Center","biomarkers":" CD20 • CD34","pipe":" | ","alterations":" CD20 positive","tags":["CD20 • CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zevalin (ibritumomab tiuxetan)"],"overall_status":"Completed","enrollment":" Enrollment 60","initiation":"Initiation: 06/01/2007","start_date":" 06/01/2007","primary_txt":" Primary completion: 02/01/2015","primary_completion_date":" 02/01/2015","study_txt":" Completion: 02/01/2015","study_completion_date":" 02/01/2015","last_update_posted":"2020-08-31"},{"id":"2c238099-8a49-42fe-a605-86b923c96e47","acronym":"","url":"https://clinicaltrials.gov/study/NCT01490723","created_at":"2021-01-18T06:14:11.343Z","updated_at":"2024-07-02T16:36:45.353Z","phase":"Phase 2","brief_title":"Zevalin-Containing Nonmyeloablative Conditioning for Stem Cell Transplantation (SCT)","source_id_and_acronym":"NCT01490723","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" CD20","pipe":"","alterations":" ","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • bendamustine • fludarabine IV • Zevalin (ibritumomab tiuxetan) • Neupogen (filgrastim)"],"overall_status":"Completed","enrollment":" Enrollment 20","initiation":"Initiation: 01/01/2013","start_date":" 01/01/2013","primary_txt":" Primary completion: 04/24/2019","primary_completion_date":" 04/24/2019","study_txt":" Completion: 04/24/2019","study_completion_date":" 04/24/2019","last_update_posted":"2020-05-05"},{"id":"38a35e63-cd3b-412b-ad56-aec50d38b4e2","acronym":"","url":"https://clinicaltrials.gov/study/NCT00662948","created_at":"2021-01-18T02:28:18.421Z","updated_at":"2024-07-02T16:36:45.554Z","phase":"Phase 2","brief_title":"ZAR2007: R-CHOP in Folicular Lymphoma Patients no Treated Previously. Consolidation With 90Y Ibritumomab Tiuxetan (Zevalin®) Versus Maintenance Treatment With Rituximab (MabThera®)","source_id_and_acronym":"NCT00662948","lead_sponsor":"PETHEMA Foundation","biomarkers":" CD20","pipe":" | ","alterations":" CD20 positive","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • Zevalin (ibritumomab tiuxetan)"],"overall_status":"Completed","enrollment":" Enrollment 149","initiation":"Initiation: 12/01/2008","start_date":" 12/01/2008","primary_txt":" Primary completion: 10/01/2014","primary_completion_date":" 10/01/2014","study_txt":" Completion: 10/30/2017","study_completion_date":" 10/30/2017","last_update_posted":"2020-04-28"},{"id":"e6b452f7-3d85-4d39-99c3-3e76b049eaa2","acronym":"","url":"https://clinicaltrials.gov/study/NCT01493479","created_at":"2021-01-18T06:15:18.779Z","updated_at":"2025-02-25T17:19:41.803Z","phase":"Phase 2","brief_title":"Phase II Study of Fractionated 90Y Ibritumomab Tiuxetan (Zevalin) Radioimmunotherapy as an Initial Therapy of Follicular Lymphoma","source_id_and_acronym":"NCT01493479","lead_sponsor":"The Christie NHS Foundation Trust","biomarkers":" CD20","pipe":" | ","alterations":" LDH elevation","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e LDH elevation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • Zevalin (ibritumomab tiuxetan)"],"overall_status":"Completed","enrollment":" Enrollment 76","initiation":"Initiation: 06/06/2007","start_date":" 06/06/2007","primary_txt":" Primary completion: 01/01/2011","primary_completion_date":" 01/01/2011","study_txt":" Completion: 11/06/2015","study_completion_date":" 11/06/2015","last_update_posted":"2019-10-15"},{"id":"df0b622d-d4e8-4611-a520-a7b2b04bc55e","acronym":"SAKK 37/05","url":"https://clinicaltrials.gov/study/NCT00392691","created_at":"2021-01-18T01:22:16.501Z","updated_at":"2024-07-02T16:36:59.577Z","phase":"Phase 1","brief_title":"Melphalan, Yttrium Y 90 Ibritumomab Tiuxetan, and Rituximab Followed by Autologous Stem Cell Transplant in Treating Older Patients With Non-Hodgkin's Lymphoma That Has Relapsed or Not Responded to Previous Treatment","source_id_and_acronym":"NCT00392691 - SAKK 37/05","lead_sponsor":"Swiss Group for Clinical Cancer Research","biomarkers":" CD20","pipe":" | ","alterations":" CD20 positive","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • vinorelbine tartrate • melphalan • Zevalin (ibritumomab tiuxetan)"],"overall_status":"Completed","enrollment":" Enrollment 20","initiation":"Initiation: 10/01/2006","start_date":" 10/01/2006","primary_txt":" Primary completion: 12/01/2012","primary_completion_date":" 12/01/2012","study_txt":" Completion: 05/01/2013","study_completion_date":" 05/01/2013","last_update_posted":"2019-05-15"},{"id":"23f00988-141d-492a-bf10-8b3f15c78220","acronym":"","url":"https://clinicaltrials.gov/study/NCT01686165","created_at":"2021-01-18T07:18:51.318Z","updated_at":"2024-07-02T16:37:07.396Z","phase":"Phase 2","brief_title":"Belinostat and Yttrium Y 90 Ibritumomab Tiuxetan in Patients W/Relapsed Aggressive B-Cell NHL","source_id_and_acronym":"NCT01686165","lead_sponsor":"University of Arizona","biomarkers":" CD20","pipe":" | ","alterations":" CD20 positive","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • Zevalin (ibritumomab tiuxetan) • Beleodaq (belinostat)"],"overall_status":"Completed","enrollment":" Enrollment 5","initiation":"Initiation: 08/31/2012","start_date":" 08/31/2012","primary_txt":" Primary completion: 02/09/2016","primary_completion_date":" 02/09/2016","study_txt":" Completion: 11/09/2017","study_completion_date":" 11/09/2017","last_update_posted":"2018-08-28"},{"id":"4727bb59-3716-4ec6-938a-4e3c0a8a5f0b","acronym":"","url":"https://clinicaltrials.gov/study/NCT00695409","created_at":"2021-01-18T02:35:58.821Z","updated_at":"2024-07-02T16:37:09.156Z","phase":"Phase 2","brief_title":"Yttrium-90 Ibritumomab Tiuxetan Plus High-Dose BEAM Followed By ASCT For Relapsed B-Cell Non-Hodgkin Lymphoma","source_id_and_acronym":"NCT00695409","lead_sponsor":"City of Hope Medical Center","biomarkers":" CD20","pipe":" | ","alterations":" CD20 positive","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cytarabine • etoposide IV • carmustine • melphalan • Zevalin (ibritumomab tiuxetan)"],"overall_status":"Completed","enrollment":" Enrollment 122","initiation":"Initiation: 03/18/2008","start_date":" 03/18/2008","primary_txt":" Primary completion: 03/27/2017","primary_completion_date":" 03/27/2017","study_txt":" Completion: 03/27/2017","study_completion_date":" 03/27/2017","last_update_posted":"2018-07-06"},{"id":"aff0350f-1e12-4fbe-82db-024d88a189d8","acronym":"","url":"https://clinicaltrials.gov/study/NCT00119392","created_at":"2021-01-18T00:24:10.457Z","updated_at":"2024-07-02T16:37:09.368Z","phase":"Phase 2","brief_title":"Yttrium Y 90 Ibritumomab Tiuxetan, Fludarabine, Radiation Therapy, and Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma","source_id_and_acronym":"NCT00119392","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • fludarabine IV • Zevalin (ibritumomab tiuxetan)"],"overall_status":"Completed","enrollment":" Enrollment 42","initiation":"Initiation: 06/01/2004","start_date":" 06/01/2004","primary_txt":" Primary completion: 07/01/2009","primary_completion_date":" 07/01/2009","study_txt":" Completion: 04/23/2016","study_completion_date":" 04/23/2016","last_update_posted":"2018-06-29"},{"id":"966249d5-1977-4634-829f-d28c0914ddd0","acronym":"ZBEAM2","url":"https://clinicaltrials.gov/study/NCT00689169","created_at":"2021-01-18T02:34:35.707Z","updated_at":"2025-02-25T17:16:22.873Z","phase":"Phase 2","brief_title":"Targeted Intensification With ZBEAM and Autologous Stem Cell Transplantation in Patients With High-grade B-Cell Lymphoma","source_id_and_acronym":"NCT00689169 - ZBEAM2","lead_sponsor":"Lymphoma Study Association","biomarkers":" CD20","pipe":" | ","alterations":" CD20 positive","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • etoposide IV • melphalan • Zevalin (ibritumomab tiuxetan)"],"overall_status":"Completed","enrollment":" Enrollment 75","initiation":"Initiation: 08/01/2007","start_date":" 08/01/2007","primary_txt":" Primary completion: 01/01/2011","primary_completion_date":" 01/01/2011","study_txt":" Completion: 01/01/2014","study_completion_date":" 01/01/2014","last_update_posted":"2018-03-07"},{"id":"5c2a1e5c-1536-4a08-af7c-14f102e0dc21","acronym":"","url":"https://clinicaltrials.gov/study/NCT00073957","created_at":"2021-01-18T00:11:41.115Z","updated_at":"2024-07-02T16:37:14.601Z","phase":"Phase 2","brief_title":"Y 90 Ibritumomab Tiuxetan \u0026Rituximab Relapsed or Refractory Diffuse Large B-Cell Non-Hodgkin's Lymphoma","source_id_and_acronym":"NCT00073957","lead_sponsor":"Beth Israel Deaconess Medical Center","biomarkers":" CD20","pipe":" | ","alterations":" CD20 positive","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • Zevalin (ibritumomab tiuxetan)"],"overall_status":"Completed","enrollment":" Enrollment 25","initiation":"Initiation: 12/01/2003","start_date":" 12/01/2003","primary_txt":" Primary completion: 01/01/2012","primary_completion_date":" 01/01/2012","study_txt":" Completion: 01/01/2012","study_completion_date":" 01/01/2012","last_update_posted":"2018-01-23"},{"id":"640df645-9d61-456c-8653-32c547a368a0","acronym":"Z-RIC-Allo","url":"https://clinicaltrials.gov/study/NCT00644371","created_at":"2021-01-18T02:23:52.585Z","updated_at":"2024-07-02T16:37:24.092Z","phase":"Phase 2","brief_title":"Allogenic Stem Cell Transplantation (SCT) With Non-myeloablative Conditioning in Patients With Relapse Non-Hodgkin's Lymphoma (NHL)","source_id_and_acronym":"NCT00644371 - Z-RIC-Allo","lead_sponsor":"Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea","biomarkers":" CD20","pipe":"","alterations":" ","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • melphalan • fludarabine IV • Zevalin (ibritumomab tiuxetan) • thiotepa"],"overall_status":"Completed","enrollment":" Enrollment 20","initiation":"Initiation: 11/01/2007","start_date":" 11/01/2007","primary_txt":" Primary completion: 02/21/2011","primary_completion_date":" 02/21/2011","study_txt":" Completion: 02/04/2013","study_completion_date":" 02/04/2013","last_update_posted":"2017-03-27"},{"id":"69e39828-4f67-49cf-822a-0cf54fbd4910","acronym":"ZEVALLO","url":"https://clinicaltrials.gov/study/NCT00607854","created_at":"2021-01-18T02:15:22.492Z","updated_at":"2025-02-25T17:15:44.692Z","phase":"Phase 2","brief_title":"Safety of Ibritumomab Tiuxetan (Zevalin®) in Combination With a Fludarabine-based Reduced Intensity Conditioning (RIC) Regimen (ZEVALLO 2007)","source_id_and_acronym":"NCT00607854 - ZEVALLO","lead_sponsor":"University Hospital, Bordeaux","biomarkers":" CD20","pipe":" | ","alterations":" CD20 positive","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fludarabine IV • Zevalin (ibritumomab tiuxetan)"],"overall_status":"Completed","enrollment":" Enrollment 31","initiation":"Initiation: 02/01/2008","start_date":" 02/01/2008","primary_txt":" Primary completion: 02/01/2011","primary_completion_date":" 02/01/2011","study_txt":" Completion: 11/01/2011","study_completion_date":" 11/01/2011","last_update_posted":"2016-10-05"}]